Results 111 to 120 of about 28,600 (213)

Backrest Position and Outcome in Comatose Survivors of Out‐of‐Hospital Cardiac Arrest: Protocol for a Multi‐Center Randomized Comparison Within the Danish Out‐of‐Hospital Cardiac Arrest (DANOHCA) Trial

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Intensive care following resuscitation from out‐of‐hospital cardiac arrest (OHCA) is based on a set of interventions, all of which are intended to reduce anoxic brain injury and improve outcomes, including sedation, mechanical ventilation, circulatory optimization, and temperature control protocols.
Jesper Kjaergaard   +13 more
wiley   +1 more source

Dexamethasone Versus Placebo in Comatose Survivors of Out‐of‐Hospital Cardiac Arrest: Study Protocol for a Multicenter Randomized Comparison Within the Danish Out‐of‐Hospital Cardiac Arrest Trial (DANOHCA)

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background The inflammatory response to whole‐body ischemia, as seen in comatose survivors after out‐of‐hospital cardiac arrest (OHCA), is associated with increased morbidity and mortality. Early high‐dose dexamethasone may dampen the inflammatory response, which may diminish secondary brain damage and other organ injury and decrease mortality.
Jo B. Andreasen   +12 more
wiley   +1 more source

Olanzapine Use and Vomiting Incidence in Chemotherapy-receiving Patients With Cervical Cancer: Multicenter Post Hoc Analysis. [PDF]

open access: yesIn Vivo
Kawamura Y   +17 more
europepmc   +1 more source

Lithium Dispensing Patterns in Dutch Youth: Prevalence, Incidence Dosages, and Duration of Use From 2011 to 2022

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Objective Bipolar disorder (BD) often emerges during mid‐adolescence and young adulthood, and leads to functional and social impairment, with a prevalence of 0.87% among Dutch youth. Lithium, the first‐line BD maintenance treatment, stabilizes mood, prevents suicide, and is well tolerated, yet its use has declined as long‐term second ...
Ravish N. Gangapersad   +8 more
wiley   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

open access: yesBritish Journal of Haematology, Volume 209, Issue 2, Page 432-440, August 2026.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte   +5 more
wiley   +1 more source

Samidorphan sadness: does the addition of samidorphan to olanzapine have prodepressive effects? [PDF]

open access: yesInt Clin Psychopharmacol
Parkerson JA   +3 more
europepmc   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang   +3 more
wiley   +1 more source

Essential medications in palliative care: an updated survey of Australian and New Zealand medical practitioners practising palliative care

open access: yesInternal Medicine Journal, Volume 56, Issue 8, Page 1361-1368, August 2026.
Abstract Background Palliative care patients experience complex symptoms requiring varied pharmacological management. Medication choice depends on the underlying aetiology of symptoms, guideline recommendations, clinician preference and medication availability.
Jack Power   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy